Survodutide 10mg

Description

Survodutide Technical Overview

Survodutide, also known as BI 456906, is an investigational peptide developed as a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R).

GLP-1R and GCGR are class B G protein-coupled receptors associated with metabolic and endocrine signaling.

Survodutide has been investigated in clinical studies involving metabolic regulation, body-weight-related outcomes, and metabolic dysfunction-associated steatohepatitis (MASH).

Clinical development findings do not establish the equivalence or safety of independently manufactured research preparations.

Compound Specifications

Storage and Handling

• Follow manufacturer-validated storage conditions.
• Protect from moisture, light, and contamination.
• Maintain appropriate handling procedures for modified peptides.

Lyophilized Format

Survodutide may be manufactured in lyophilized form. Stability depends on formulation and chemical modifications.

Research Use Disclaimer

Survodutide is an investigational research compound. This preparation is not represented as an FDA-approved pharmaceutical product and is not intended for human or veterinary administration.

Frequently Asked Questions

What Is Survodutide?

An investigational dual glucagon receptor and GLP-1 receptor agonist.

What Is BI 456906?

The development designation for Survodutide.

Which Receptors Does It Activate?

GCGR and GLP-1R.

How Does Survodutide Differ From Semaglutide?

Survodutide is a dual GCGR/GLP-1R agonist, while Semaglutide primarily activates GLP-1R.

What Research Areas Involve Survodutide?

Metabolic signaling, receptor pharmacology, and experimental liver-related metabolic biology.

Survodutide Research Overview

Survodutide has been investigated in metabolic research involving simultaneous activation of glucagon and GLP-1 receptor pathways.

GLP-1 Receptor Research

Research examines GLP-1R-mediated signaling and endocrine cellular responses.

Glucagon Receptor Research

GCGR activation has been investigated in hepatic metabolic regulation and related pathways.

Dual Receptor Pharmacology

Clinical and experimental studies have examined the combined receptor activity of Survodutide.

Metabolic Liver Research

Clinical investigations have included people with metabolic dysfunction-associated steatohepatitis.

Research Applications

References

1. Survodutide Phase 2 Metabolic Research — PubMed.
2. Survodutide and Steatohepatitis Research — PubMed.

Certificate of Analysis (COA)

Documentation should establish Survodutide molecular identity, chemical modifications, purity, and actual peptide content.

Peptide Lives